HANNAH ALISON L. 4

What Happened

• Hannah Alison, a director of Rigel Pharmaceuticals (RIGL), was reported as the recipient of 5,750 shares via a restricted stock unit (RSU) award dated 2026-05-15. The transaction is recorded as an award/acquisition (code A) at $0.00 per share (no cash paid).

Key Details

• Transaction date: 2026-05-15 (reported on Form 4 filed 2026-05-19).
• Transaction type/code: Award / Acquisition (A).
• Shares involved: 5,750 common shares; reported acquisition price $0.00 (total cash = $0).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The RSUs convert to common stock upon vesting; they shall fully vest on the date prior to the company's next Annual Meeting, contingent on the director’s continuous service on the Board.
• Filing timeliness: Form 4 was filed 2026-05-19 for a 2026-05-15 transaction — within the standard two-business-day reporting window (timely).

Context

• This was an equity award (RSUs), not a market purchase or sale. RSU awards are common for director compensation and do not involve immediate cash outlay or a market transaction until/if shares vest and are delivered.
• Such awards are generally routine and reflect compensation/retention, not necessarily a direct signal of the insider’s view of the stock.